Cargando…
The amyloid-β(1–42)-oligomer interacting peptide D-AIP possesses favorable biostability, pharmacokinetics, and brain region distribution
We have previously developed a unique 8-amino acid Aβ42 oligomer-Interacting Peptide (AIP) as a novel anti-amyloid strategy for the treatment of Alzheimer’s disease. Our lead candidate has successfully progressed from test tubes (i.e., in vitro characterization of protease-resistant D-AIP) to transg...
Autores principales: | Shobo, Adeola, James, Nicholas, Dai, Daniel, Röntgen, Alexander, Black, Corbin, Kwizera, Jean-Robert, Hancock, Mark A., Huy Bui, Khanh, Multhaup, Gerhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752909/ https://www.ncbi.nlm.nih.gov/pubmed/34896396 http://dx.doi.org/10.1016/j.jbc.2021.101483 |
Ejemplares similares
-
Aβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and function
por: Barucker, Christian, et al.
Publicado: (2015) -
Structural conversion of neurotoxic amyloid-β(1–42) oligomers to fibrils
por: Ahmed, Mahiuddin, et al.
Publicado: (2010) -
Amyloid β Regulates the Expression and Function of AIP1
por: Wang, Huaiming, et al.
Publicado: (2014) -
Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers
por: Wang, Hansen, et al.
Publicado: (2017) -
Critical aggregation concentration for the formation of early Amyloid-β (1–42) oligomers
por: Novo, Mercedes, et al.
Publicado: (2018)